Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating - Novo Nordisk (NYSE:NVO)

Loading...Loading...BMO Capital Markets initiated coverage on Danish drug maker Novo Nordisk A/S NVO after the company garnered interest as it hit the holy grail with the next generation of famed weight loss and diabetes drugs. The analyst writes that an in-depth analysis of the growing obesity and adjacent metabolic disease market suggests Eli Lilly And Co LLY and Novo Nordisk will remain the two entrenched players in this duopoly. While other players are just entering the obesity landscape, Novo has been ...